ArticleNature2021
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 1 synthesis or guideline pooled it, 156 citations in OpenAlex.
- A multiplexed in vivo approach to identify driver genes in small cell lung cancer.Cell reports · 2023Pooled it
- Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition.Nature immunology · 2026Article
- Article
- Article
- Stage-Specific Degradation of Cyclin D3 Orchestrates Myelopoiesis and Restrains Myeloproliferative Neoplasm Development.Cancer research · 2026Article
- Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening.Neuro-oncology · 2026Article
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.Nature reviews. Drug discovery · 2026Review
- Article
- Molecular diversity of mitochondrial autophagy receptors: context-dependent effects in human health and disease.Cell death discovery · 2026Review
- Ubiquitin-dependent degradation of p27Kip1 and p21Waf1/Cip1 by AMBRA1 ensures G1 and S phase progression and limits replication stress.Nucleic acids research · 2026Article
- Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells.FEBS open bio · 2026Article
- A novel synthetic melanin as a potential anticancer agent that induces apoptosis and cyclin D downregulation through distinct pathways.The Journal of biological chemistry · 2026Article
- CRL4EMBO reports · 2026Article
- Autophagy-Apoptosis Crosstalk in Cancer: Mechanisms, Signaling Pathways, and Therapeutic Targeting.Cancers · 2026Review
- Article
- A proteome-wide dependency map of protein interaction motifs.Nature structural & molecular biology · 2026Article
- Pre-dauer starvation rapidly and reversibly reduces niche proliferative signaling to the Caenorhabditis elegans germ line.Development (Cambridge, England) · 2026Article
- Article
- DCAF12 Ubiquitin Ligase Promotes Lung Cancer Metastasis by Modulating the TRiC/CCT Chaperonin Complex.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 4 institutions in 1 country.
Andrea C ChaikovskyDepartment of Pediatrics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1842-5384
Chuan LiDepartment of Biology, Stanford University, Stanford, CA, USA.
Edwin E JengDepartment of Genetics, Stanford University, Stanford, CA, USA.
Samuel LoebellDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Myung Chang LeeDepartment of Pediatrics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-7051-5822
Christopher W MurrayDepartment of Genetics, Stanford University, Stanford, CA, USA.
Ran ChengDepartment of Biology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-7617-3018
Janos DemeterDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-7301-8055
Danielle L SwaneyDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Si-Han ChenDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2890-9764
Billy W NewtonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Jeffrey R JohnsonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Alexandros P DrainasDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Yan Ting ShueDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Jose A SeoaneDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3856-9177
Preethi SrinivasanDepartment of Genetics, Stanford University, Stanford, CA, USA.
Andy HeDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Akihiro YoshidaDepartment of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Susan Q HipkinsDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Edel McCreaDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Carson D PoltorackDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Nevan J KroganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4902-337X
J Alan DiehlDepartment of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-9854-5049
Christina KongDepartment of Pathology, Stanford University, Stanford, CA, USA.
Peter K JacksonDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
Christina CurtisDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0166-3802
Dmitri A PetrovDepartment of Biology, Stanford University, Stanford, CA, USA.
Michael C BassikDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-5185-8427
Monte M WinslowDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5730-9573
Julien SageDepartment of Pediatrics, Stanford University, Stanford, CA, USA. julsage@stanford.edu.ORCID http://orcid.org/0000-0002-8928-9968
Stanford University · USGladstone Institutes · USCase Western Reserve University · USStanford Medicine · US
Funding
Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MX-ray Screening and Rapid Structure DeterminationP50AI150476 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANKEL, ALAN D · 2019 to 2021
$14.4MUsing Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY · 2017 to 2021
$10.9MGenomics of rapid adaptation in the lab and in the wildR35GM118165 · NIGMS · STANFORD UNIVERSITY · PI Dmitri Petrov · 2016 to 2026
$8.3MInvestigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategiesR35CA231997 · NCI · STANFORD UNIVERSITY · PI SAGE, JULIEN · 2019 to 2025
$6.2MNuclear Accumulation of D-type Cyclins and OncogenesisR01CA093237 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DIEHL, JOHN ALAN · 2001 to 2022
$5.9MMolecular basis of tumor suppression by Cdk4/6 inhibitionR01CA228413 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI RUBIN, SETH MICHAEL, SAGE, JULIEN · 2019 to 2023
$1.8MMechanisms of Cell Cycle and Cell Identity Regulation that Influence Sensitivity to Targeted TherapiesF99CA245471 · NCI · STANFORD UNIVERSITY · PI CHAIKOVSKY, ANDREA CHRISTINE · 2019 to 2020
$78kNCI NIH HHS F99 CA245471NCI NIH HHS R01 CA093237NCI NIH HHS R01 CA228413NCI NIH HHS R35 CA231997NCI NIH HHS T32 CA009302NCI NIH HHS U54 CA209891NIAID NIH HHS P50 AI150476NIGMS NIH HHS R35 GM118165NIGMS NIH HHS T32 GM007276
Abstract
The initiation of cell division integrates a large number of intra- and extracellular inputs. D-type cyclins (hereafter, cyclin D) couple these inputs to the initiation of DNA replication
Indexed as
Adaptor Proteins, Signal TransducingAdenocarcinoma of LungAnimalsCell DivisionCyclin DCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Genes, Tumor SuppressorHumansLung NeoplasmsMicePiperazinesPyridinesU937 CellsUbiquitinationAdaptor Proteins, Signal TransducingAMBRA1 protein, humanAmbra1 protein, mouseCyclin DCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPiperazinesPyridines
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.